FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953006917> ?p ?o ?g. }

• W2953006917 abstract "Background: Baricitinib is an oral selective JAK1/2 inhibitor recently approved in the EU for the treatment of rheumatoid arthritis (RA). No real-life data are available about its efficacy and safety. Objectives: To investigate the efficacy and safety profiles of baricitinib in a real-life setting. Methods: We performed a multicenter prospective observational study on adult RA patients starting JAK inhibitors between 12/2017 and 12/2018. Demographic and clinical data as well as laboratory values and adverse events were collected at baseline and after 12 and 24 weeks. Disease activity was measured by DAS28-CRP at baseline, after 12 and 24 weeks. Results: We obtained data from 150 patients with RA (women 116 – 77.3%; median age 60 years, inter-quartile range IQR 54-68; median disease duration 10 years, IQR 4-18) treated with baricitinib 2 or 4 mg QD, however only 2/150 (1.3%) at the reduced dosage. At the time of database lock 95/150 (63%) patients have completed the 12 weeks follow-up, 38/150 (25%) patients have completed the 24 weeks follow-up. Baricitinib was started after at least one conventional synthetic DMARD in all 148/150 cases (99%), being in all of cases methotrexate, while was started prior to a biologic DMARD in 57 (38%) patients. It was prescribed as a second line in 17/93 (18%) patients, third in 27 (29%), fourth or higher in 49 (53%). Baricitinib was prescribed as monotherapy in 57/150 (38%) patients, while combined with methotrexate in 65/150 (43%), at a median dosage of 15 mg/week. Oral corticosteroids were used by 105/150 (70%) patients, at a median dosage of 5 mg/day. Mean DAS28-CRP at baseline was 4.92 (standard deviation 1.22), with 65 (43.3%) patients having a DAS28-CRP>5.1. At both 12 and 24 weeks, a significant reduction of disease activity scores was observed (DAS28-CRP mean 3.07, SD 1.36, and 2.85, SD 1.35, respectively; p values Conclusion: In our real-world dataset, baricitinib is effective in reducing RA disease activity, after 12 weeks, being generally well-tolerated with few severe adverse events. Disclosure of Interests: Giacomo Maria Guidelli: None declared, Elena Generali: None declared, Chiara Bazzani: None declared, Roberto Gorla: None declared, Garifallia Sakellariou: None declared, Massimiliano Limonta: None declared, Maria Sole Chimenti: None declared, Roberto Perricone: None declared, Edoardo Conticini: None declared, Bruno Frediani: None declared, nicola boffini: None declared, Lorenzo Dagna Consultant for: Prof Lorenzo Dagna received consultation honoraria from Abbvie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Novartis, Pfizer, Sanofi-Genzyme, and SOBI., Marta Riva: None declared, Maria Rosa Pozzi: None declared, Rosa Daniela Grembiale Grant/research support from: BMS, Consultant for: JANSSEN, CELGENE, Speakers bureau: PFIZER, JANSSEN, BMS, NOVARTIS, Teodora Serban: None declared, Gerolamo Bianchi Consultant for: Alfa-Sigma, Amgen, BMS, Celgene, Medac, UCB, Speakers bureau: Abbvie, Abiogen, Alfa-Sigma, Amgen, BMS, Celgene, Carlo Selmi Grant/research support from: Abbvie, Janssen, MSD, Novartis, Pfizer, Consultant for: Abbvie, Alfa-Sigma, Biogen, BMS, Celgene, Eli-Lilly, GSK, Janssen, Merck Sharp and Dohme, Novartis, Pfizer, Roche, Sanofi-Genzyme, YCB, Speakers bureau: Abbvie, Alfa-Sigma, Biogen, BMS, Celgene, Eli-Lilly, GSK, Janssen, Merck Sharp and Dohme, Novartis, Pfizer, Roche, Sanofi-Genzyme, YCB" @default.
• W2953006917 created "2019-06-27" @default.
• W2953006917 creator A5002277651 @default.
• W2953006917 creator A5003030575 @default.
• W2953006917 creator A5007677152 @default.
• W2953006917 creator A5012379045 @default.
• W2953006917 creator A5016051239 @default.
• W2953006917 creator A5018866927 @default.
• W2953006917 creator A5021692873 @default.
• W2953006917 creator A5025015625 @default.
• W2953006917 creator A5027512145 @default.
• W2953006917 creator A5032563375 @default.
• W2953006917 creator A5053063613 @default.
• W2953006917 creator A5054036074 @default.
• W2953006917 creator A5055989807 @default.
• W2953006917 creator A5056220378 @default.
• W2953006917 creator A5064128395 @default.
• W2953006917 creator A5065292366 @default.
• W2953006917 creator A5069560703 @default.
• W2953006917 creator A5077324156 @default.
• W2953006917 date "2019-06-01" @default.
• W2953006917 modified "2023-09-26" @default.
• W2953006917 title "AB0446 REAL-LIFE USE OF BARICITINIB IN RHEUMATOID ARTHRITIS: A MULTICENTER OBSERVATIONAL STUDY OF 150 PATIENTS" @default.
• W2953006917 cites W2016300251 @default.
• W2953006917 cites W2118945736 @default.
• W2953006917 cites W2127409504 @default.
• W2953006917 cites W2155702314 @default.
• W2953006917 doi "https://doi.org/10.1136/annrheumdis-2019-eular.7681" @default.
• W2953006917 hasPublicationYear "2019" @default.
• W2953006917 type Work @default.
• W2953006917 sameAs 2953006917 @default.
• W2953006917 citedByCount "1" @default.
• W2953006917 countsByYear W29530069172021 @default.
• W2953006917 crossrefType "proceedings-article" @default.
• W2953006917 hasAuthorship W2953006917A5002277651 @default.
• W2953006917 hasAuthorship W2953006917A5003030575 @default.
• W2953006917 hasAuthorship W2953006917A5007677152 @default.
• W2953006917 hasAuthorship W2953006917A5012379045 @default.
• W2953006917 hasAuthorship W2953006917A5016051239 @default.
• W2953006917 hasAuthorship W2953006917A5018866927 @default.
• W2953006917 hasAuthorship W2953006917A5021692873 @default.
• W2953006917 hasAuthorship W2953006917A5025015625 @default.
• W2953006917 hasAuthorship W2953006917A5027512145 @default.
• W2953006917 hasAuthorship W2953006917A5032563375 @default.
• W2953006917 hasAuthorship W2953006917A5053063613 @default.
• W2953006917 hasAuthorship W2953006917A5054036074 @default.
• W2953006917 hasAuthorship W2953006917A5055989807 @default.
• W2953006917 hasAuthorship W2953006917A5056220378 @default.
• W2953006917 hasAuthorship W2953006917A5064128395 @default.
• W2953006917 hasAuthorship W2953006917A5065292366 @default.
• W2953006917 hasAuthorship W2953006917A5069560703 @default.
• W2953006917 hasAuthorship W2953006917A5077324156 @default.
• W2953006917 hasBestOaLocation W29530069171 @default.
• W2953006917 hasConcept C126322002 @default.
• W2953006917 hasConcept C141071460 @default.
• W2953006917 hasConcept C159110408 @default.
• W2953006917 hasConcept C197934379 @default.
• W2953006917 hasConcept C23131810 @default.
• W2953006917 hasConcept C2777575956 @default.
• W2953006917 hasConcept C2779951463 @default.
• W2953006917 hasConcept C2781059491 @default.
• W2953006917 hasConcept C44249647 @default.
• W2953006917 hasConcept C68443243 @default.
• W2953006917 hasConcept C71924100 @default.
• W2953006917 hasConceptScore W2953006917C126322002 @default.
• W2953006917 hasConceptScore W2953006917C141071460 @default.
• W2953006917 hasConceptScore W2953006917C159110408 @default.
• W2953006917 hasConceptScore W2953006917C197934379 @default.
• W2953006917 hasConceptScore W2953006917C23131810 @default.
• W2953006917 hasConceptScore W2953006917C2777575956 @default.
• W2953006917 hasConceptScore W2953006917C2779951463 @default.
• W2953006917 hasConceptScore W2953006917C2781059491 @default.
• W2953006917 hasConceptScore W2953006917C44249647 @default.
• W2953006917 hasConceptScore W2953006917C68443243 @default.
• W2953006917 hasConceptScore W2953006917C71924100 @default.
• W2953006917 hasLocation W29530069171 @default.
• W2953006917 hasOpenAccess W2953006917 @default.
• W2953006917 hasPrimaryLocation W29530069171 @default.
• W2953006917 hasRelatedWork W2327874801 @default.
• W2953006917 hasRelatedWork W2342222516 @default.
• W2953006917 hasRelatedWork W2417298481 @default.
• W2953006917 hasRelatedWork W2947617747 @default.
• W2953006917 hasRelatedWork W2947702376 @default.
• W2953006917 hasRelatedWork W2950439404 @default.
• W2953006917 hasRelatedWork W2950645712 @default.
• W2953006917 hasRelatedWork W2951119587 @default.
• W2953006917 hasRelatedWork W2951649807 @default.
• W2953006917 hasRelatedWork W3033193114 @default.
• W2953006917 hasRelatedWork W3034499092 @default.
• W2953006917 hasRelatedWork W3035658255 @default.
• W2953006917 hasRelatedWork W3041179836 @default.
• W2953006917 hasRelatedWork W3042997347 @default.
• W2953006917 hasRelatedWork W3044793204 @default.
• W2953006917 hasRelatedWork W3082566691 @default.
• W2953006917 hasRelatedWork W3106519634 @default.
• W2953006917 hasRelatedWork W3110783179 @default.
• W2953006917 hasRelatedWork W3163972763 @default.
• W2953006917 hasRelatedWork W3164551000 @default.
• W2953006917 isParatext "false" @default.
• W2953006917 isRetracted "false" @default.

• next